Silverarc Capital Management’s Akero Therapeutics AKRO Stock Holding History

Silverarc Capital Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-25,000	Closed	-$1.33M	–	83
2025 Q2	$1.33M	Sell	25,000 -155,600	-86%	-$7.07M	0.25%	53
2025 Q1	$7.31M	Sell	180,600 -39,400	-18%	-$1.67M	1.5%	21
2024 Q4	$6.12M	Buy	+220,000	New	+$6.66M	1.34%	27
2023 Q4	–	Sell	-200,000	Closed	-$10.1M	–	70
2023 Q3	$10.1M	Sell	200,000 -36,500	-15%	-$1.7M	3.07%	7
2023 Q2	$11M	Buy	+236,500	New	+$10.8M	3.42%	9
2023 Q1	–	Sell	-150,000	Closed	-$8.22M	–	73
2022 Q4	$8.22M	Buy	+150,000	New	+$6.43M	2.35%	14

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Silverarc Capital Management's AKRO Position: Q4 2025 in Review

Silverarc Capital Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 643,636 shares — an estimated $30.6M sold.

Silverarc Capital Management first reported a position in AKRO in Q4 2020 and held it in 17 quarters. The position peaked at $38.1M in Q2 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Silverarc Capital Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Silverarc Capital Management sold 643,636 Akero Therapeutics shares in Q4 2025, an estimated $30.6M.
Silverarc Capital Management first reported a position in Akero Therapeutics in Q4 2020 and held it in 17 quarters.
Silverarc Capital Management's Akero Therapeutics position peaked at $38.1M in Q2 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Silverarc Capital Management's 13F filing for Q4 2025, filed 12 Feb 2026.